Category: Blog

If I ever have the need to share something work or non work related it will be here.

Speaking at NeurIPS 2026: World Models for High-Stakes Health

Speaking at NeurIPS 2026: World Models for High-Stakes Health

I am excited to share that I will be speaking at the upcoming NeurIPS 2026 Workshop on World Models for High-Stakes Health (WMHS) in Atlanta, Georgia on December 12, 2026.

Healthcare has leveraged machine learning to model disease progression, treatment outcomes, and operations for decades. However, the emerging frontier is whether world models can reliably generalize across heterogeneous patient populations, complex interventions, clinical workflows, and diverse care settings—while remaining rigorous and precise about uncertainty and the deep biological unknowns inherent in clinical data.

“For me, the key opportunity is not simply better prediction. It is creating systems that continuously learn from decisions, observations, outcomes, and feedback. If successful, world models could become a foundation for patient simulation, clinical development intelligence, and more adaptive healthcare systems.”

The workshop convenes leading researchers and practitioners across machine learning, clinical development, and trustworthy AI to explore:

  • Patient World Models: Learning from longitudinal, multimodal clinical data and patient timelines.
  • Clinical Trial Simulation: Virtual trial arms, synthetic controls, and external control cohorts to de-risk development.
  • Intervention-Aware Reasoning: Counterfactual outcome prediction, causal representation learning, and treatment effect modelling.
  • Continuous Learning Loops: Closing the gap between predictions, decisions, real-world observations, and model refinement.

I look forward to discussing both the immense opportunities and the open challenges with an exceptional community of collaborators and organizers from Novartis, IQVIA, GSK, AstraZeneca, Microsoft, NVIDIA, University of Toronto / Vector Institute, Columbia, and Oxford.

For more details on the program and call for papers, visit the WMHS @ NeurIPS 2026 website, or join the discussion on LinkedIn.

Beyond Human Performance: Multi-Agent AI for GxP-Compliant Pharma Manufacturing

Beyond Human Performance: Multi-Agent AI for GxP-Compliant Pharma Manufacturing

In high-stakes pharmaceutical manufacturing, visual quality control and automated defect detection are critical for maintaining regulatory compliance and ensuring patient safety. Our recent paper, “Beyond Human Performance: A Vision-Language Multi-Agent Approach for Quality Control in Pharmaceutical Manufacturing”, explores how specialized vision-language multi-agent architectures can collaborate to detect subtle particulate, packaging, and vial defects with unprecedented precision—surpassing traditional baseline computer vision and human inspection thresholds.

By leveraging consensus mechanisms, specialized domain agents, and explainable audit trails, this multi-agent system provides both high accuracy and the rigorous validation required for GxP-compliant manufacturing environments.

Authors: Subhro Jyoti Mandal, Leila Rachidi, Prakhar Jain, Matthieu Duvinage, Sander W. Timmer
Preprint: arXiv:2602.20543
Direct PDF: Download Paper PDF (arXiv)

New Chapter: Leading AI & Data Science in Global Drug Development at Novartis

New Chapter: Leading AI & Data Science in Global Drug Development at Novartis

I am excited to announce a new chapter in my career: I have joined Novartis in Basel as the Global Head of Data Science and AI for Global Drug Development.

My mission is clear: to accelerate how we bring medicines to patients. The opportunity is unprecedented. AI can fundamentally change the speed and precision of drug development—from candidate optimization through clinical trials and CMC to regulatory submission.

Novartis has one of the industry’s most innovative pipelines. My focus will be on building AI capabilities and solutions that compress timelines at scale without compromising rigor. We will be applying Digital Twins, Agentic Systems, and Decision Intelligence to the toughest problems in global drug development.

On a personal note, my family and I are excited to make Switzerland our new home. Time to hit the slopes!

Connect with me on LinkedIn to follow our progress.

GSK Case Study: Building a Registry of Truth for Global AI Ops

GSK Case Study: Building a Registry of Truth for Global AI Ops

Weights & Biases has published a detailed case study on our work at GSK, highlighting how we built a “Registry of Truth” to scale AI operations across a global manufacturing network.

The case study dives into our TwinOps strategy, which uses Digital Twins to optimize vaccine production through real-time monitoring and control. By leveraging W&B Weave for tracing agentic workflows and the W&B Model Registry as a centralized lens across multi-cloud environments (Azure, GCP, Databricks), we’ve been able to:

  • Transition from reactive ‘monthly PDF’ reporting to proactive, automated drift detection.
  • Optimize yield across 13 key products, reducing variability in complex bioprocesses.
  • Track tangible business value—such as extra vaccine doses produced—through a real-time dashboard.

This infrastructure was a critical pillar in our mission to reach 2.5 billion patients. You can read the full technical breakdown here: GSK: Optimizing the pharmaceutical supply chain with W&B.

Speaking at Weights & Biases Fully Connected: The Era of Physical AI

Speaking at Weights & Biases Fully Connected: The Era of Physical AI

I recently had the pleasure of speaking at the Weights & Biases Fully Connected event in London. In my talk, I explored the transition from traditional Digital AI to the next frontier: Physical AI.

The core of our discussion centered on how foundation models and agentic systems are moving beyond chatbots to interact with the physical world—from global supply chains to complex biomanufacturing processes. I shared insights into the AIGA framework, which we developed to orchestrate autonomous workflows that detect anomalies, hypothesize root causes, and simulate decision impacts with full GxP-level traceability.

Physical AI and Agentic Architecture at GSK

In an industry where the stakes are as high as patient safety, we must move beyond static dashboards. The future lies in agentic systems that record the ‘basis and history’ of every decision more precisely than ever before, paving the way for Vision-Language-Action (VLA) models and true digital transformation in manufacturing.

Read the full case study and event details here: Weights & Biases GSK Customer Story and Weights & Biases Fully Connected London.

Databricks Data & AI summit speaker

Databricks Data & AI summit speaker

Databricks Data + AI Summit 2024 - Healthcare and Life Sciences Industry Forum

Healthcare and Life Sciences Industry Forum – Data + AI Summit | Databricks

Join me at the Data & AI Summit to explore how these technologies are not just shaping the future of healthcare and life sciences, but also providing actionable insights that can lead to real-world solutions and advancements in the field. Let’s connect and propel the conversation forward, unlocking new possibilities and transforming the landscape of data intelligence. See you there!